Atea Pharmaceuticals (AVIR) Cash & Equivalents (2019 - 2026)

Atea Pharmaceuticals' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $79.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 33.57% year-over-year to $79.3 million; the TTM figure through Mar 2026 stood at $79.3 million (down 33.57% YoY), while the FY2025 annual figure was $95.7 million, down 78.78% from the prior year.
• Cash & Equivalents was $79.3 million for Q1 2026 at Atea Pharmaceuticals, down from $95.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $705.5 million in Q1 2022 to a low of $77.3 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $263.2 million across 5 years, with a median of $176.4 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents surged 244.48% in 2024, then plunged 83.72% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $188.5 million in 2022, then fell by 23.69% to $143.8 million in 2023, then jumped by 213.59% to $451.0 million in 2024, then slumped by 78.78% to $95.7 million in 2025, then retreated by 17.13% to $79.3 million in 2026.
• The last three Cash & Equivalents figures came in at $79.3 million (Q1 2026), $95.7 million (Q4 2025), and $77.3 million (Q3 2025), per Business Quant data.